How we can help
Healthcare and life sciences businesses face unique pressures: stringent regulation, fast-paced innovation, and growing global competition. We understand this environment because we work within it, advising the full range of participants – from universities and research institutes, biotech and digital health start-ups, peak bodies, private health insurers, hospitals, aged care and NDIS providers, and regulators; through to ASX-listed and multinational biopharmaceutical and medical device companies – on the challenges that matter most to their businesses.
We cover the full lifecycle of your business: capital raising, M&A, IP protection, clinical trials and research governance, manufacturing and facilities, data privacy, and regulatory compliance across therapeutic goods, Medicare, PBS, NDIS and healthcare practitioner regulation, including regulatory investigations and parliamentary inquiries. We also bring strategic depth that goes beyond legal advice: we support market access and reimbursement strategy, including health technology assessments and medicines and chemicals scheduling submissions – because getting to market is only part of the challenge.
We are committed to the industry we serve and are members of ANDHealth, BioNSW, the BioMelbourne Network and the Consumer Healthcare Products Association, maintaining ongoing engagement with the sector's peak regulators.
Experience
-
4DMedical
Longstanding adviser to 4DMedical since its $193m IPO in 2020, supporting the company across multiple capital raisings, strategic acquisitions, therapeutic goods regulation, ASX compliance, and key distribution agreements driving its international expansion. -
PanAscea
Advised a clinical-stage biotechnology company developing novel therapeutics for sepsis. Acting on company's governance, capital raising, commercialisation strategy and clinical development program, including its ongoing Australia-wide Phase Ib clinical trials. -
Australian Health Practitioners Regulation Agency
Acts for AHPRA and the National Boards in connection with enforcement proceedings that arise under the Health Practitioner Regulation National Law. -
Releaf Australia
Acted in respect of an investigation by the Therapeutic Goods Administration into allegations of therapeutic goods advertising contraventions. -
DKSH
Advised on the acquisition of leading Australian healthcare professional engagement company, Hahn Healthcare, marking an expansion of DKSH’s market coverage across Asia Pacific, operating as DKSH Healthcare Australia. -
Vacenti Aged Care
Advised on the $185.6m sale of its aged care business and assets - including six operational facilities, one nearing completion and surplus land - to Estia Health, navigating Commonwealth and state aged care regulatory regimes under a compressed timeframe with coordinated multi-asset completions. -
Sonic Clinical Services
Advised on the $54m acquisition of the National Skin Cancer Centres group, a portfolio of 30 clinics across Australia offering skin cancer and aesthetic services. -
Ryman Healthcare
Advised on the secondary listing of its shares on the ASX, supporting the dual-listed aged care and retirement living operator to commence trading with a market capitalisation of approximately $2.5bn. -
Juno Pharmaceuticals
Prepared submission on behalf of company in respect of the Federal Government’s review into the Efficient Funding of Chemotherapy program. -
Down Under Enterprises, Bush Pharmacy and New Directions Australia
Advised patentees in Federal Court proceedings involving therapeutic-use patent claims, including patent and trade mark infringement, passing off and misleading or deceptive conduct claims.